$150m facility is South Korean group’s joint investment with sovereign wealth fund INA
SK Plasma’s nearly completed blood plasma fractionation plant in Karawang, West Java, will be the first of its kind in Indonesia. (Indonesia Investment Authority)
NATSUMI KAWASAKI
December 19, 2025 12:18 JST
KARAWANG, Indonesia — South Korean biopharmaceutical company SK Plasma’s factory in Indonesia is nearing completion, with commercial mass production expected to start in the second half of 2026.